Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer

Journal of Controlled Release

Volumn 210, Issue , 2015, Pages 26-38

  Zalba, Sara ^a,b   Contreras, Ana M ^a   Haeri, Azadeh ^b   Ten Hagen, Timo L M ^b   Navarro, Iñigo ^a   Koning, Gerben ^b   Garrido, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cetuximab; Colorectal cancer; EGFR; Fab ; Oxaliplatin; Targeted liposomes

Indexed keywords

ANTIBODIES; BIOLOGICAL MATERIALS; CELL CULTURE; CHEMOTHERAPY; DISEASES; DRUG THERAPY; ENZYME INHIBITION; MOBILE SECURITY; MONOCLONAL ANTIBODIES; TUMORS;

CETUXIMAB; COLORECTAL CANCER; COLORECTAL CANCERS (CRC); EGFR; EPIDERMAL GROWTH FACTOR RECEPTORS; INTRACELLULAR DRUG DELIVERY; MONOCLONAL ANTIBODIES (MAB); OXALIPLATIN;

LIPOSOMES;

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; NANOCARRIER; OXALIPLATIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SELECTIVITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGAND BINDING; MOUSE; MULTIPLE CYCLE TREATMENT; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIPOSOMES; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 84929625414     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.271     Document Type: Article

References (46)

1. B.W. Harper Advances in platinum chemotherapeutics Chemistry 16 24 2010 7064 7077
2. D. Liu Application of liposomal technologies for delivery of platinum analogs in oncology Int. J. Nanomedicine 8 2013 3309 3319
3. A. Stein, and D. Arnold Oxaliplatin: a review of approved uses Expert. Opin. Pharmacother. 13 1 2012 125 137
4. F. Levi Oxaliplatin: pharmacokinetics and chronopharmacological aspects Clin. Pharmacokinet. 38 1 2000 1 21
5. S. Zalba, and M.J. Garrido Liposomes, a promising strategy for clinical application of platinum derivatives Expert Opin. Drug Deliv. 10 6 2013 829 844
6. A. Gabizon Emerging role of liposomal drug carrier systems in cancer chemotherapy J. Liposome Res. 13 1 2003 17 20
7. S.M. Moghimi, and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog. Lipid Res. 42 6 2003 463 478
8. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzym. Regul. 41 2001 189 207
9. T.M. Allen, and P.R. Cullis Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Deliv. Rev. 65 1 2013 36 48
10. E. Ruoslahti, S.N. Bhatia, and M.J. Sailor Targeting of drugs and nanoparticles to tumors J. Cell Biol. 188 6 2010 759 768
11. V.P. Torchilin Drug targeting Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S81 S91
12. V.P. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging AAPS J. 9 2 2007 E128 E147
13. A.S. Manjappa Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor J. Control. Release 150 1 2011 2 22
14. Y.L. Lin Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients PLoS One 9 2 2014 e86789
15. B. Vincenzi The biological properties of cetuximab Crit. Rev. Oncol. Hematol. 68 2 2008 93 106
16. N. Yarom, and D.J. Jonker The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer Discov. Med. 11 57 2011 95 105
17. V. Deschoolmeester A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist 15 7 2010 699 731
18. C.M. Rocha-Lima EGFR targeting of solid tumors Cancer Control 14 3 2007 295 304
19. G.A. Koning Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison Pharm. Res. 20 8 2003 1249 1257
20. P. Holliger, and P.J. Hudson Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 9 2005 1126 1136
21. S. Zalba Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo Eur. J. Pharm. Biopharm. 81 2 2012 273 280
22. S. Song Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo Int. J. Pharm. 363 1-2 2008 155 161
23. M. Rothdiener Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes Methods Mol. Biol. 624 2010 295 308
24. J. Beuttler Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL) Bioconjug. Chem. 20 6 2009 1201 1208
25. G. Rouser, S. Fkeischer, and A. Yamamoto Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots Lipids 5 5 1970 494 496
26. A. Hioki Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature Biol. Pharm. Bull. 33 9 2010 1466 1470
27. C.W. Lowik Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red Anal. Biochem. 213 2 1993 426 433
28. R. Wild Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels Mol. Cancer Ther. 5 1 2006 104 113
29. S. Skvortsov Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor Proteomics Clin. Appl. 2 6 2008 908 914
30. M. Shimizu (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells Clin. Cancer Res. 11 7 2005 2735 2746
31. P.C. Lee Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody Biomaterials 34 34 2013 8756 8765
32. P. Sapra Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments Clin. Cancer Res. 10 3 2004 1100 1111
33. B.A. Baldo Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses Oncoimmunology 2 10 2013 e26333
34. J.W. Park Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 4 2002 1172 1181
35. C.L. Waite, and C.M. Roth Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities Crit. Rev. Biomed. Eng. 40 1 2012 21 41
36. A. Abu-Lila Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model J. Control. Release 134 1 2009 18 25
37. B.P. Gray, M.J. McGuire, and K.C. Brown A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density PLoS One 8 8 2013 e72938
38. A. Beduneau Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab′ fragments Biomaterials 28 33 2007 4978 4990
39. S.B. Howell Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs Mol. Pharmacol. 77 6 2010 887 894
40. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 4 2005 307 320
41. C. Riganti Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells Mol. Pharm. 8 3 2011 683 700
42. D.L. Iden, and T.M. Allen In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach Biochim. Biophys. Acta 1513 2 2001 207 216
43. D. Goren Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies Br. J. Cancer 74 11 1996 1749 1756
44. A.S. Abu Lila Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor J. Control. Release 142 2 2010 167 173
45. C. Yang Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma BMC Biotechnol. 11 2011 21
46. P. Simard, and J.C. Leroux In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen Mol. Pharm. 7 4 2010 1098 1107